A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Sponsor:

Daiichi Sankyo Pharma

Sponsor Study ID:

DS6000-109

CTO #:

104020

NCT Number:

NCT06161025

Phase:

II/III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Other Female Genital; Ovary

Study Objectives:

To evaluate BICR- assessed ORR at each dose level of R-DXd. To evaluate investigator assessed ORR at each dose level of R-DXd. To evaluate the DoR at each dose level of R-DXd.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)